OS Therapies (OSTX)
Develops Listeria immunotherapy for recurrent metastatic osteosarcoma after surgery.
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program Interim 3-year Overall Survival data expected in early September 2026 ahead of MHRA Statistical Methods Scientific Advice Meeting for Conditional MAA submission acceptance criteria Final 3-year Overall Survival data to be included in FDA BLA Accelerated Approval Program submission ahead of Type B Pre-BLA Meeting previously granted in Q2/26 U.K. waives Pediatric Investigation Plan (PIP) requirement New York and Rockville, Maryland--(Newsfile Corp. - August 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today reported financial results for the second fiscal quarter ended June 30, 2026, and provided business and regulatory updates. The Company is seeking to obtain a Biologics License Application (BLA) under the Accelerated Approval Program of the U.S. Food & Drug Administration (FDA), and equivalent Conditional Marketing Accelerated Authorisations (CMAAs) from the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA), for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program").
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings
OS Therapies Incorporated (NYSE:OSTX) shares are up during Tuesday's premarket session as the company recently announced that its Phase 2b trial of OST-HER2 achieved statistically significant overall survival results at the 2.5-year mark.
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies advanced materially through late-stage regulatory and commercialization preparation as OST-HER2 moved from Phase 2bsupported planning toward a more defined global approval pathway in recurrent, fully resected, pulmonary metastatic osteosarcoma.
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public. So what: If you purchased OS Therapies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti.
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of OS Therapies Incorporated (NYSE American: OSTX) resulting from allegations that OS Therapies may have issued materially misleading business information to the investing public. So what: If you purchased OS Therapies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti.
OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings
OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) by the end of the first quarter of 2026.
OS Therapies Incorporated (NYSEAMERICAN:OSTX) Sees Large Growth in Short Interest
OS Therapies Incorporated (NYSEAMERICAN:OSTX - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 623,422 shares, a growth of 60.2% from the December 15th total of 389,268 shares. Approximately 2.0% of the company's shares are sold short.
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
OS Therapies Incorporated (NYSE: OSTX) shares are down on Thursday following the announcement of positive biomarker data from its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, a type of bone cancer.
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026) OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date OSAH to focus primarily on the re-establishment of USDA conditional approval and commercialization of immunotherapy OST-HER2 for canine osteosarcoma and other HER2 positive cancers in animals OST-HER2 featured in 2025 2x Emmy-nominated and Anthem Award-winning documentary 'Shelter Me: Cancer Pioneers' streaming on PBS OSTX reiterates release date of January 15, 2026 for biomarker data from Phase 2b OST-HER2 trial in human pulmonary metastatic osteosarcoma that will be used to support upcoming Biologics License Application submission with US FDA New York, New York--(Newsfile Corp. - January 14, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that its wholly-owned subsidiary OS Animal Health Corp (OSAH) has filed a Form S-1 with the Securities Exchange Commission (SEC) in preparation for an Initial Public Offering (IPO). OSAH intends to list on either the NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026).
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating OS Therapies Incorporated (NYSE American: OSTX) on behalf of the company's shareholders. The investigation seeks to determine whether OS Therapies's directors breached their fiduciary duties in connection with recent corporate actions.
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
Dallas, Texas--(Newsfile Corp. - November 21, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies advanced key clinical, regulatory, and commercial milestones in 3Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma.
Os Therapies Posts Wider Loss in Q2
Os Therapies (OSTX 5.83%), a clinical-stage biotechnology company focused on immunotherapies for rare pediatric cancers, released earnings for Q2 2025 on August 19, 2025. The most important news in the release highlighted continued progress toward regulatory milestones for its lead drug candidate, OST-HER2, alongside deepening financial losses. Net loss per share was $0.19. Reported EPS of $0.19 was below the analyst estimate of -$0.12 per share for Q2 2025. No revenue was recorded in the period, aligning with consensus, as Os Therapies remains pre-commercial. Operating losses were approximately 2.9 times higher than in the second quarter of 2024, driven by ramped-up regulatory and clinical activity. Overall, the quarter showcased major advances for OST-HER2’s potential approval but underscored the company’s persistent need for capital and ongoing expense escalation. Source: Analyst estimates for the quarter provided by FactSet. Os Therapies develops immunotherapies to address untreated or under-treated forms of cancer, with a core focus on pediatric osteosarcoma. The company’s lead asset, OST-HER2, is an immunotherapy. This drug candidate targets a rare bone cancer that has seen little innovation in four decades. The business pursues accelerated development for OST-HER2, leveraging multiple FDA special designations that support quick regulatory review and potential market exclusivity. Recent efforts center on two main directions: advancing OST-HER2 through pivotal regulatory milestones in the U.S. and abroad, and strategically expanding intellectual property. Os Therapies also seeks to broaden its pipeline with the acquisition of clinical and preclinical immunotherapy assets and by developing new antibody-drug conjugate platforms for solid tumors. Success factors for the company hinge on positive trial data, regulatory achievements, strategic partnering, and effective commercialization strategy for its therapies. Net loss per share was $0.19, which was below the analyst estimate of -$0.115, and Operating loss was $4.537 million for Q2 2025. This represents an increase of approximately 191.5% compared to the $1.557 million net operating loss in Q2 2024, highlighting a dramatic acceleration in spending. Management attributed this rise to escalating regulatory and clinical trial activities, particularly costs associated with advancing OST-HER2 through the pivotal Phase 2b trial and regulatory discussions with global agencies during Q2 2025. On the clinical side, the Phase 2b trial for OST-HER2 produced several strong data points. Patients receiving OST-HER2 had a 12-month event-free survival rate of 35 %, while historical controls registered 20 %, with a p-value of 0.0197. Interim 2-year overall survival among treated patients reached 66.6 % (out of 27 patients) versus 40 % for controls (p = 0.0046) for updated interim 2-year overall survival data from the Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma. No patients experienced serious (grade 4 or 5) treatment-associated side effects. These results provided momentum for further regulatory engagement and substantiated the safety profile of the therapy. Interim data was presented at the MIB Factor conference on June 28, 2025. Regulatory progress was a defining element of the quarter. The U.S. Food and Drug Administration (FDA) confirmed that OST-HER2 meets the criteria for Regenerative Medicine Advanced Therapy designation, opening the path for expedited review. The FDA assigned a Biologics License Application (BLA) number, with an End of Phase 2 meeting scheduled for August 27, 2025, to finalize preparations for an Accelerated Approval submission. Internationally, the company submitted an Innovative Licensing and Access Pathway (ILAP) application to the UK regulator and requested a rapporteur meeting with the European Medicines Agency for October. Os Therapies made several moves to position itself for future product launches and pipeline expansion. It announced a commercial partnership with Eversana to prepare for a potential U.S. launch of OST-HER2 in the first half of 2026 and began the necessary state licensing processes. The acquisition of Ayala Pharmaceuticals’ listeria immunotherapy platform brought in additional clinical-stage and preclinical programs alongside patent protection until 2040. The creation of subsidiaries—including OS Animal Health, aimed at veterinary applications of OST-HER2—expanded the company’s potential market and set the groundwork for broader commercial activities. The launch of OS Drug Conjugates underscores an ongoing focus on antibody-drug conjugate technology for various solid tumor indications. Capital management remained a major focus for the quarter. The company completed a $4.2 million capital raise through warrant exercises shortly after period end. This transaction boosted Os Therapies’ cash reserves and provided management with a cash runway extending into mid-2026. Additionally, the company established an at-the-market equity sales agreement allowing up to $18 million in future fundraising, building financial flexibility at the cost of potential further dilution. Management pointed investors to the potential sale of a priority review voucher, a special regulatory incentive that could be granted if OST-HER2 is approved by September 30, 2026. Recent sales of such vouchers ranged from $155 million to $160 million in May and June 2025, presenting a possible source of non-dilutive capital. Despite these developments, the immediate financial picture was one of continued losses and a reliance on capital markets as regulatory activities intensify. The company also gained inclusion in the Russell Microcap index, which may support liquidity and institutional investor interest. No formal guidance was provided for upcoming quarters or fiscal 2025. Management communicated that the current cash position, bolstered by recent fundraising, is expected to last through mid-2026. All forward-looking commentary centered on executing regulatory milestones, such as the BLA submission, FDA meeting dates, and international approvals for OST-HER2. Major upcoming events include the End of Phase 2 meeting with the FDA on August 27, 2025, a planned BLA submission in late Q3 2025, and critical decision points with UK and European authorities in the second half of the year. With no revenue at this stage and an increasing burn rate, investors will be watching the progress of regulatory reviews and OST-HER2’s potential approval timeline, as well as any inflection points in non-dilutive funding such as a possible priority review voucher sale or business development deals. OSTX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
OS Therapies Announces Warrant Exercise Inducement & Exchange Offer
NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced a warrant exercise inducement and exchange offer to holders of its five-year warrants with a current exercise price of $1.12 per share that were issued in connection with a PIPE financing transaction that had an initial closing date of December 31, 2024 (the “Old Warrants”). The Company is offer.
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended March 31, 2025 and provided a business update. “The first quarter of 2025 was a crucial execution quarter for OS Therapies, as we announced positive data from our OST-HER2 Phase 2b clinical trial in the prevention of recurrent, fully resected, lung metastat.
OS Therapies FDA Meeting Request Granted
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food & Drug Administration (“FDA”) granted the Company's meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA.
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment
The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology-using naturally occurring canine cancers as research models-are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that's evolving faster than ever before. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges.OS Therapies (NYSE-A: OSTX) is focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company's lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company's growth isn't limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer.Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption-more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the "Exclusively Pediatric" designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One's pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million-largely due to R&D and launch costs-the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer.GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK's experimental antibody-drug conjugates (ADCs) that targets B7-H3-a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who've already gone through two lines of treatment. That's a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK's drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK's pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year-including a relaunch of its blood cancer drug Blenrep-the company looks well-positioned to keep growing in high-need treatment areas.ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company's growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company's profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: markrmckelvie@gmail.com City: NAPLES State: Florida Country: United States Website: https://razorpitch.com/ Source: www.abnewswire.com .(C) 2025 M2 COMMUNICATIONS, source M2 PressWIRE
OS Therapies to Host Analyst Day at NYSE on April 7, 2025
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the Company will be hosting an Analyst Day at the New York Stock Exchange in Lower Manhattan that will start at 10am on Monday, April 7, 2025. The Company intends to focus the Analyst Day discussion on: OST-HER2 program for human recurrent, fully resected lung metastatic osteosarcoma that is bei.
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended December 31, 2024 and provided a business update. “2024 was a transformative year for OS Therapies as we completed our initial public offering and finalized the treatment phase of our Phase 2b clinical trial in the prevention of recurrence in fully resected, lu.
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company's participation aligns with its prior.
Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature OS Therapies' Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company's rapidly advancing pipel.